A Trial to Investigate the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 2017-12-21
• Target enrollment: 0
• Participant gender: All

Summary

This is a bicentric, double-blinded, randomised, four-period crossover phase 1 trial, using automated 30-hour euglycemic clamp in subjects with type 2 diabetes mellitus.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Adocia
• Treatments: Biphasic Insulins; Insulin Lispro; Insulin, Isophane

Criteria

Inclusion Criteria:

• Male or female subject aged 18-70 years (both inclusive)

• Type 2 diabetes mellitus (as diagnosed clinically) for ≥ 12 months

• HbA1c level between 6.5% and 9.0 % (both inclusive)

• Body mass index between 20.0 and 40.0 kg/m2 (both inclusive)

• Body weight <= 125.0 kg at the screening visit

• Insulin-treated subjects. Total insulin dose of <= 1.2 (I)U/kg/day

Exclusion Criteria:

• Type 1 diabetes mellitus

• Known or suspected hypersensitivity to IMP(s) or related products

• Previous participation in this trial. Participation is defined as randomised.

• Receipt of any medicinal product in clinical development within 60 days before randomisation in this trial.

• Clinically significant abnormal values for haematology, biochemistry, coagulation, or urinalysis as judged by the Investigator considering the underlying disease.

• Supine blood pressure at screening (after resting for at least 5 min in supine position) outside the range of 90-160 mmHg systolically or 50-95 mmHg diastolically (excluding white-coat hypertension; therefore, if a repeated measurement shows values within the range, the subject can be included in the trial); symptoms of arterial hypotension and/or a heart rate at rest outside the range of 50-90 beats per minute. This exclusion criterion also pertains to subjects being on anti-hypertensives.

• Women of child bearing potential not willing to use contraceptive methods.